Research Reports

Summary

Tivic Health Systems, Inc. (TIVC) changed its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol to VBIO, effective April 28, 2026, reflecting a strategic transformation into a late-stage biopharmaceutical company anchored by Entolimod™ and supported by its wholly owned CDMO subsidiary Velocity Bioworks.

Key takeaways

Corporate name changed from Tivic Health Systems, Inc. to Valion Bio, Inc., effective April 28, 2026 — signals formal completion of strategic pivot from consumer medical devices to biopharmaceuticals.

Ticker symbol changed from TIVC to VBIO on Nasdaq Capital Market, expected effective April 28, 2026 — impacts trading, investor identification, and index eligibility.

Name change was effected via Certificate of Amendment filed April 22, 2026, under Delaware law without shareholder vote — confirms unilateral board authority and no dilution or rights impact.

Rebrand reflects acquisition of Velocity Bioworks in December 2025 for $16.3 million and consolidation of Entolimod™ development under CEO Michael K. Handley — establishes integrated biomanufacturing and late-stage asset control.

Entolimod™ is advanced under FDA’s Animal Rule with Fast Track and Orphan Drug designations for Acute Radiation Syndrome, with active engagement toward U.S. Strategic National Stockpile procurement — introduces potential non-dilutive, nine-figure revenue pathway.

Velocity Bioworks completed 200-fold Entolimod scale-up using 50-liter fermentation — validates internal manufacturing capability critical for government procurement and third-party CDMO revenue generation.

Full analysis

This filing documents a high-materiality corporate rebranding that marks the culmination of a deliberate strategic transformation. The name change to Valion Bio, Inc. and ticker change to VBIO are not cosmetic but legally codify a fundamental shift: the company has fully exited its legacy consumer medical device business and now operates as a vertically integrated late-stage biopharmaceutical platform. Central to this pivot is Entolimod™, a TLR5 agonist with over 15 years of development history and $140 million in cumulative investment, now positioned for U.S. government procurement under the Animal Rule pathway — a regulatory advantage that de-risks clinical execution and opens a potential nine-figure non-dilutive revenue opportunity via the Strategic National Stockpile. Critically, the acquisition of Velocity Bioworks in December 2025 for $16.3 million provides domestic, controlled biomanufacturing capacity, recently validated by a successful 200-fold scale-up of Entolimod production. This integration enables supply chain security — a prerequisite for government partnerships — while also establishing a standalone CDMO revenue stream targeting underserved Phase I/II biologics clients. Leadership consolidation under CEO Michael K. Handley, who previously led Entolimod’s advancement at Statera Biopharma, further strengthens execution credibility. The rebrand thus represents a material inflection point: investors are now engaging with a company defined by a government-priority asset, proven manufacturing scalability, and a dual-revenue model — one anchored in national preparedness procurement and the other in commercial CDMO services — all under a new corporate identity designed to signal this evolved strategic reality to capital markets, partners, and agencies.